Advertisement

Comparison of MS inflammatory activity in women using continuous versus cyclic combined oral contraceptives

Published:February 05, 2020DOI:https://doi.org/10.1016/j.msard.2020.101970

      Highlights

      • We evaluated whether MS activity was lower in continuous, vs. cyclic, oral contraceptive (OC) users.
      • Neither relapse rate or time to new relapse was different between the two groups.
      • Continuous OC users had longer time to new inflammatory brain lesion formation.

      Abstract

      Background

      Many women with multiple sclerosis (MS) report fluctuating symptoms across their menstrual cycle. Oral contraceptives (OCs) alter hormonal levels across the menstrual cycle. While cyclic OCs administer hormones for 21 days, followed by a week of placebo, continuous OCs can administer continuous doses of hormones for up to 3 months. Previous studies have suggested that OC use is associated with lower MS-related inflammation. We hypothesized that due to reduced hormonal fluctuations, women with MS might experience less inflammatory activity (clinical relapses+MRI) on continuous OCs than on cyclic OCs.

      Methods

      We performed a retrospective analysis of prospectively collected data. For women with MS aged 18–50 seen at the UCSF Center for MS and Neuroinflammation, we extracted data on OC use from the Electronic Medical Records (EMR). All variables were confirmed using manual clinical chart review. We identified 19 women with relapsing forms of MS on continuous OCs and matched them (2:1 when possible) to women on cyclic OCs for OC formulation, age, MS duration and DMT type. Inflammatory activity in the two groups was then compared using log-rank tests (time to new relapse, new T2-weighted lesion formation, and gadolinium-enhancing lesion formation) and t-tests (annualized relapse rate). We also performed subgroup analyses in women with at least 1 year (N = 28) and 2 years (N = 21) of clinical observation. A power calculation was performed.

      Results

      There was no difference in time to relapse (p = 0.50) between continuous and cycling OC users. However, continuous OC users showed a statistical trend to longer time to T2 lesion formation (p = 0.09) and longer time to contrast-enhancing lesion formation (p = 0.05). In patients with at least 1 year of observation, there was a significant difference in time to T2 lesion formation (p = 0.03) and time to contrast-enhancing lesion formation (p = 0.02).

      Conclusion

      In this exploratory study, women on continuous OCs showed a trend towards less inflammatory activity on MRI relative to women on cyclic OCs. This difference was not reflected in relapse rates. We estimate that 342 patients would be required for an adequately powered cohort study to evaluate such an effect. Our findings provide reassurance that for women using continuous OCs to alleviate menstrual fluctuations in symptoms, there is not an increase in MS-related inflammatory activity.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bansil S.
        • Lee H.J.
        • Jindal S.
        • Holtz C.R.
        • Cook S.D.
        Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis.
        Acta Neurol. Scand. 1999; 99: 91-94
        • Benlloch-Navarro S.
        • Trachsel-Moncho L.
        • Fernández-Carbonell Á.
        • Olivar T.
        • Soria J.M.
        • Almansa I.
        • Miranda M.
        Progesterone anti-inflammatory properties in hereditary retinal degeneration.
        . 2019; 189: 291-301https://doi.org/10.1016/j.jsbmb.2019.01.007
        • Daniels K.
        • Abma J.C.
        Current Contraceptive Status Among Women Aged 15–49.
        United States, 2015–2017 8. 2018;
        • De Bondt T.
        • De Belder F.
        • Vanhevel F.
        • Jacquemyn Y.
        • Parizel P.M.
        Prefrontal GABA concentration changes in women-Influence of menstrual cycle phase, hormonal contraceptive use, and correlation with premenstrual symptoms.
        Brain Res. 2015; 1597: 129-138
        • De Bondt T.
        • Smeets D.
        • Pullens P.
        • Van Hecke W.
        • Jacquemyn Y.
        • Parizel P.M.
        Stability of resting state networks in the female brain during hormonal changes and their relation to premenstrual symptoms.
        Brain Res. 2015; 1624: 275-285
        • Edelman A.
        • Micks E.
        • Gallo M.F.
        • Jensen J.T.
        • Grimes D.A.
        Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.
        Cochrane Database Syst. Rev. 2014; Cd004695
        • Holmqvist P.
        • Hammar M.
        • Landtblom A.M.
        • Brynhildsen J.
        Symptoms of multiple sclerosis in women in relation to cyclical hormone changes.
        Eur. J. Contracept. Reprod. Health Care. 2009; 14: 365-370
        • Jones J.
        • Mosher W.
        • Daniels K.
        Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995.
        Nat. Health Stat. Rep. 2012; : 1-25
        • Oertelt-Prigione S.
        Immunology and the menstrual cycle.
        Autoimmun. Rev. 2012; 11: A486-A492
        • Pozzilli C.
        • De Giglio L.
        • Barletta V.T.
        • Marinelli F.
        • Angelis F.D.
        • Gallo V.
        • Pagano V.A.
        • Marini S.
        • Piattella M.C.
        • Tomassini V.
        • Pantano P.
        Oral contraceptives combined with interferon beta in multiple sclerosis.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e120
        • Pozzilli C.
        • Falaschi P.
        • Mainero C.
        • Martocchia A.
        • D'Urso R.
        • Proietti A.
        • Frontoni M.
        • Bastianello S.
        • Filippi M.
        MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns.
        Neurology. 1999; 53: 622-624
        • Smirnova T.G.
        • Savochkina A.Y.
        • Dolgushin I.I.
        • Nikushkina K.V.
        • Samuseva I.V.
        Changes in functional activity of neutrophils and monocytes isolated from the peripheral blood of women at different phases of the menstrual cycle.
        Bull. Exp. Biol. Med. 2018; 166: 222-224
        • Zorgdrager A.
        • De Keyser J.
        Menstrually related worsening of symptoms in multiple sclerosis.
        J. Neurol. Sci. 1997; 149: 95-97
        • Zorgdrager A.
        • De Keyser J.
        The premenstrual period and exacerbations in multiple sclerosis.
        Eur. Neurol. 2002; 48: 204-206